Orca-T significantly improved cGVHD-free survival compared to allo-HSCT, with a 78% vs 38% rate at one year. The study reported a 94% overall survival rate for Orca-T, with no new safety concerns ...
The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...
Orca-T significantly improved survival free of moderate-to-severe cGvHD compared to alloHSCT, with rates of 78% versus 38%. Orca-T demonstrated a lower incidence of severe acute GvHD and non-relapse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results